Abstract
The treatment of malignant lymphoma has undergone major changes in recent years. ABVD with or without radiotherapy for untreated Hodgkin lymphoma (HL) and CHOP-based combination therapy with anti-CD20 antibody rituximab for B cell non-Hodgkin lymphoma (B-NHL) have long been the standard of care. Type II anti-CD20 antibody obinutuzumab combination chemotherapy has become a new treatment option for indolent-B-NHL, and an antibody-drug conjugate against CD30 brentuximab vedotin combination chemotherapy has become the new treatment of choice for advanced-stage HL and CD30-positive T-NHL.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
